The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome
Open accessAbstract
// Yi Huang 1,2,* , Chunling Ma 1,3,4,* , Qunyuan Zhang 5 , Jian Ye 1 , Fang Wang 1,6 , Yanping Zhang 7 , Pamela Hunborg 7 , Mark A. Varvares 8 , Daniel F. Hoft 1 , Eddy C. Hsueh 7 and Guangyong Peng 1 1 Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, USA 2 Center for Clinical Molecular Medicine, Children’s Hospital of Chongqing Medical University, Chongqing, P. R. China 3 Department of Laboratory Medicine, Women and Children’s Health Care Hospital of Linyi City, Linyi, P. R. China 4 Molecular Biology Experimental Center, Shandong Medical College, Linyi, P. R. China 5 Department of Genetics, Washington University School of Medicine in St. Louis, Saint Louis, MO, USA 6 Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China 7 Department of Surgery, Saint Louis University School of Medicine, Saint Louis, MO, USA 8 Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, Saint Louis, MO, USA * These authors are contributed equally to this work Correspondence to: Eddy C. Hsueh, email: // Guangyong Peng, email: // Keywords : CD4 + T cells; CD8 + T cells; regulatory T cells; Th17 cells; breast tumor microenvironment Received : February 11, 2015 Accepted : April 09, 2015 Published : April 29, 2015 Abstract The Cancer Immunoediting concept has provided critical insights suggesting dual functions of immune system during the cancer initiation and development. However, the dynamics and roles of CD4 + and CD8 + T cells in the pathogenesis of breast cancer remain unclear. Here we utilized two murine breast cancer models (4T1 and E0771) and demonstrated that both CD4 + and CD8 + T cells were increased and involved in immune responses, but with distinct dynamic trends in breast cancer development. In addition to cell number increases, CD4 + T cells changed their dominant subsets from Th1 in the early stages to Treg and Th17 cells in the late stages of the cancer progression. We also analyzed CD4 + and CD8 + T cell infiltration in primary breast cancer tissues from cancer patients. We observed that CD8 + T cells are the key effector cell population mediating effective anti-tumor immunity resulting in better clinical outcomes. In contrast, intra-tumoral CD4 + T cells have negative prognostic effects on breast cancer patient outcomes. These studies indicate that CD4 + and CD8 + T cells have opposing roles in breast cancer progression and outcomes, which provides new insights relevant for the development of effective cancer immunotherapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 5×
“It is established that an effective anti-tumor immune response requires the involvement of both CD4+ and CD8+ T cells [11-14].”
InfluentialThe immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 1×
“Increasing evidence suggests that tumor-specific tumor-infiltrating T cells (TILs) but not circulating T cells predict clinical outcomes of cancer patients [26-28].”
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672 · cited 1×
“CD4+ T cells are critical for priming of tumor-specific CD8+ T cells and for the seconary expansion and memory of CD8+ T cells as well [15, 16].”
Tumor microenvironments direct the recruitment and expansion of human Th17 cells
Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., & Peng, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902813 · Cited by 324
Self-citationGeneration and regulation of human CD4 + IL-17-producing T cells in ovarian cancer
Miyahara, Y., Odunsi, K., Chen, W., Peng, G., Matsuzaki, J., & Wang, R.-F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710686105 · Cited by 279
Self-citationYe, J., Ma, C., Hsueh, E. C., Eickhoff, C. S., Zhang, Y., Varvares, M. A., Hoft, D. F., & Peng, G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202369 · Cited by 203
Self-citationHuman regulatory T cells induce T-lymphocyte senescence
Ye, J., Huang, X., Hsueh, E. C., Zhang, Q., Ma, C., Zhang, Y., Varvares, M. A., Hoft, D. F., & Peng, G. (2012) · Blood · doi:10.1182/blood-2012-03-416040 · Cited by 198
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Teaching an old dog new tricks: next-generation CAR T cells
Tokarew, N., Ogonek, J., Endres, S., von Bergwelt-Baildon, M., & Kobold, S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0325-1 · Cited by 440
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
“For example, in breast cancer, significantly increased CD8+ T cells at tumor sites have been shown to have an inverse correlation with advanced tumor stages and a positive correlation with clinical outcomes [41,49,50].”
Background
Metadata
- Authors
- Huang, Y., Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Hunborg, P., Varvares, M. A., Hoft, D. F., Hsueh, E. C., & Peng, G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-04-29
- Volume
- 6
- Issue
- 19
- Pages
- 17462-17478
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2137018390
- Cited by
- 220
- References
- 9
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.